EP1206463A4 - Fatty acid synthase inhibitors - Google Patents

Fatty acid synthase inhibitors

Info

Publication number
EP1206463A4
EP1206463A4 EP00957681A EP00957681A EP1206463A4 EP 1206463 A4 EP1206463 A4 EP 1206463A4 EP 00957681 A EP00957681 A EP 00957681A EP 00957681 A EP00957681 A EP 00957681A EP 1206463 A4 EP1206463 A4 EP 1206463A4
Authority
EP
European Patent Office
Prior art keywords
fatty acid
acid synthase
synthase inhibitors
inhibitors
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00957681A
Other languages
German (de)
French (fr)
Other versions
EP1206463A1 (en
Inventor
Siegfried B Christensen Iv
Robert A Daines
Jack D Leber
Joseph Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1206463A1 publication Critical patent/EP1206463A1/en
Publication of EP1206463A4 publication Critical patent/EP1206463A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00957681A 1999-08-23 2000-08-23 Fatty acid synthase inhibitors Withdrawn EP1206463A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15027699P 1999-08-23 1999-08-23
US150276P 1999-08-23
PCT/US2000/023073 WO2001014362A1 (en) 1999-08-23 2000-08-23 Fatty acid synthase inhibitors

Publications (2)

Publication Number Publication Date
EP1206463A1 EP1206463A1 (en) 2002-05-22
EP1206463A4 true EP1206463A4 (en) 2003-01-29

Family

ID=22533807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00957681A Withdrawn EP1206463A4 (en) 1999-08-23 2000-08-23 Fatty acid synthase inhibitors

Country Status (4)

Country Link
EP (1) EP1206463A4 (en)
JP (1) JP2003507467A (en)
AU (1) AU6926500A (en)
WO (1) WO2001014362A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335673B2 (en) 2000-08-11 2008-02-26 Kaken Pharmaceutical Co., Ltd. 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
AU2014249003A1 (en) 2013-03-13 2015-10-15 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of FASN
CN103539668B (en) * 2013-10-22 2015-07-01 山西省化工研究所（有限公司） Process for synthesizing terephthalal diethyl dimalonate ultraviolet light absorber
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528977A (en) * 1966-12-14 1970-09-15 Colgate Palmolive Co Substituted t-aminophenylalanines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2137211B1 (en) * 1971-05-17 1974-08-02 Bouchara Emile
IT1177966B (en) * 1984-08-14 1987-09-03 Medosan Ind Biochimi AMIDIC DERIVATIVES OF BUTYRIC ACID 2- (P-AMINOBENZYL) AND RELATED E-STERIES PROVIDED WITH HYPOLIPIDEMIZING ACTIVITY
JPH04120040A (en) * 1990-09-11 1992-04-21 Sumitomo Chem Co Ltd Optically active phenol derivative and production thereof
JPH04124158A (en) * 1990-09-12 1992-04-24 Sumitomo Chem Co Ltd Optically active phenol derivative and its production
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528977A (en) * 1966-12-14 1970-09-15 Colgate Palmolive Co Substituted t-aminophenylalanines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0114362A1 *

Also Published As

Publication number Publication date
WO2001014362A1 (en) 2001-03-01
EP1206463A1 (en) 2002-05-22
AU6926500A (en) 2001-03-19
JP2003507467A (en) 2003-02-25

Similar Documents

Publication Publication Date Title
GB2351077B (en) Improved acid corrosion inhibitor
GB9900416D0 (en) Inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
IL145764A0 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
AU2001270200A1 (en) Fatty acid synthase inhibitors
HK1054038A1 (en) Substituted n-benzyl-indol-3-yl gloyoxylic acid derivatives having an antitumural effect
AU2001281059A1 (en) Fatty acid synthase inhibitors
IL148324A0 (en) Fatty acid synthase inhibitors
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU2001271531A1 (en) Fatty acid synthase inhibitors
GB9924522D0 (en) Enzyme inhibitors
EP1153022A4 (en) Prothease inhibitors
GB0030284D0 (en) Enzyme inhibitors
HK1047928A1 (en) Fatty acid synthase inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
AU2002243439A1 (en) Fatty acid synthase inhibitors
AU2001274940A1 (en) Fatty acid synthase inhibitors
EP1206463A4 (en) Fatty acid synthase inhibitors
AU2001271718A1 (en) Fatty acid synthase inhibitors
EP1318806A4 (en) Fatty acid synthase inhibitors
GB2389113B (en) B-secretase inhibitor
AU2001284705A1 (en) Fatty acid synthase inhibitors
IL129500A0 (en) Fatty acid derivatives II
GB0017435D0 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
GB9929340D0 (en) Inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020304

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021212

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 315/00 A

Ipc: 7C 07D 229/00 B

Ipc: 7A 61K 31/19 B

Ipc: 7C 07D 317/00 B

Ipc: 7C 07D 317/68 B

Ipc: 7C 07D 317/14 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040302